Welcome to our dedicated page for Tivic Health Systems news (Ticker: TIVC), a resource for investors and traders seeking the latest updates and insights on Tivic Health Systems stock.
Valion Bio, formerly Tivic Health Systems, reports developments tied to its transformation into a biopharmaceutical company focused on innate-immune therapeutics. Company news centers on Entolimod™, a TLR5 agonist lead candidate for acute radiation syndrome, related gastrointestinal radiation-injury work, broader oncology supportive-care applications, and pipeline depth from Entolasta™.
Updates also cover the company’s wholly owned Velocity Bioworks subsidiary, a full-service CDMO providing analytical testing, process development, and cellular and biologic therapy manufacturing services. Recurring announcements include government and public-health preparedness engagement, nonclinical study agreements, financial results, corporate presentations, leadership changes, and the completed name and ticker change from TIVC to VBIO.
Tivic Health, a health technology company focused on bioelectronic medicine, will showcase its FDA-approved ClearUP device at HLTH from November 13-16 in Las Vegas. ClearUP treats sinus pain and congestion caused by colds and allergies. Recently, Tivic announced a definitive agreement to acquire the Reliefband product line for nausea treatment, integrating wearable FDA-cleared therapeutics. The firm aims to enhance consumer awareness of bioelectronic therapies, backed by clinical studies indicating significant symptom reduction.
Tivic Health Systems, a commercial-phase health technology company, is set to announce its third-quarter 2022 financial results via conference call and webcast on November 14, 2022, at 1:30 PM PT.
Shareholders can submit questions until 5:00 PM ET on November 11, 2022. The company specializes in non-invasive bioelectronic treatments aimed at inflammation and related conditions. For more details, visit Tivic Health.
Tivic Health Systems (Nasdaq: TIVC), a leader in bioelectronic medicine, announced that CEO Jennifer Ernst will present at The ThinkEquity Conference on October 26, 2022, in New York City. This event marks a significant opportunity for the company to showcase its innovative, non-invasive treatments for inflammation and related conditions.
The conference will take place at the Mandarin Oriental Hotel, providing a platform for industry insights and networking.
Tivic Health Systems (NASDAQ: TIVC) has announced a definitive agreement to acquire the Reliefband product line, expanding its portfolio in the bioelectronic treatment of nausea. The deal, valued at up to $33.5 million, aims to leverage Reliefband's FDA-cleared products, which cater to a growing market projected at $2.4 billion in the US. This acquisition is anticipated to increase revenue opportunities significantly, combining direct-to-consumer sales with clinical applications.
Tivic Health Systems (Nasdaq: TIVC) announced that CEO Jennifer Ernst will present at the Fifth Bioelectronic Medicine Summit on October 11-12, 2022 in Garden City, NY. The summit will focus on the commercialization journey of neurotechnology. The conference aims to spotlight bioelectronic medicine's role in healthcare advancements, with discussions regarding current challenges and future developments. Tivic Health is a health technology company specializing in non-invasive bioelectronic treatments for inflammation and related conditions.
Tivic Health Systems, a commercial-phase health technology company focused on bioelectronic medicine, announced that CEO Jennifer Ernst will present at the 148th National Investment Banking Association (NIBA) conference. The event is set to take place on September 7-8, 2022, at Margaritaville Beach Resort, Hollywood, FL. NIBA has significantly impacted the micro-cap investment community since 1982, raising over $30 billion and facilitating around 90% of IPOs valued under $20 million. Tivic Health develops non-invasive treatments for inflammation-related conditions.
Tivic Health (TIVC) reported remarkable financial results for Q2 2022, posting a 97% revenue increase to $528,000 compared to $268,000 in Q2 2021. The company achieved a stunning 265% growth in unit sales via direct-to-consumer channels. Despite rising costs, the average sales cost decreased from $97.18 to $90.26. R&D expenses rose to $497,000 due to team expansions, while sales and marketing expenditures surged to $1.1 million, reflecting strategic investments. However, these developments led to a net loss of $3 million, worsening from $1.1 million in the same quarter last year.
Tivic Health® Systems, Inc. (Nasdaq: TIVC), a health technology firm focused on bioelectronic medicine, will report its financial results for Q2 2022 on August 15, 2022. The earnings call will begin at 1:30 PM PT / 4:30 PM ET, with a conference call for investors and analysts available via toll-free and international lines. Shareholders can also submit questions by August 11, 2022, at ir@tivichealth.com. More information can be found at Tivic Health's website.
Tivic Health Systems, Inc. (TIVC) announced that its ClearUP® Sinus Pain Relief device has been awarded the Most Innovative Sinus Relief Solution for 2022 by Global Health & Pharma. This recognition marks the second consecutive year for ClearUP, which is FDA-cleared and clinically proven to alleviate sinus pain and congestion. The company aims to further develop bioelectronic treatments for various conditions, reflecting a shift towards non-invasive medical solutions. Recent accolades enhance Tivic's visibility in the health tech space, signaling strong market potential.
Tivic Health Systems (Nasdaq: TIVC) announced its Annual General Meeting of Shareholders to be held virtually on June 14, 2022, at 10:00 AM PDT. This format aims to ensure accessibility for all shareholders. Related documents and information can be found on Tivic Health's website and the SEC's website. The company specializes in non-invasive bioelectronic treatments for inflammation and related conditions. Forward-looking statements in the release highlight inherent risks and uncertainties affecting future performance.